These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25992784)

  • 21. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
    Osuga K; Murakami T; Nakata S; Tomoda K; Nagano H; Monden M; Nakamura H
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2114-7. PubMed ID: 15628754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Kanekawa T; Nagai H; Kanayama M; Sumino Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatic Arterial Infusion Chemotherapy Using a Reservoir for Advanced Hepatocellular Carcinoma].
    Sato T; Takahashi Y; Imai M; Isokawa O
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):73-7. PubMed ID: 26809529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
    J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
    Kim BK; Park JY; Choi HJ; Kim DY; Ahn SH; Kim JK; Lee DY; Lee KH; Han KH
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):659-67. PubMed ID: 20552225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy.
    Shao YY; Liang PC; Wu YM; Huang CC; Huang KW; Cheng JC; Hsu CH; Hsu C; Cheng AL; Lin ZZ
    Liver Int; 2013 Oct; 33(9):1413-9. PubMed ID: 23714197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
    Woo HY; Bae SH; Park JY; Han KH; Chun HJ; Choi BG; Im HU; Choi JY; Yoon SK; Cheong JY; Cho SW; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):373-82. PubMed ID: 19763572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
    J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
    Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
    Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
    Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
    Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
    Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lai YC; Shih CY; Jeng CM; Yang SS; Hu JT; Sung YC; Liu HT; Hou SM; Wu CH; Chen TK
    World J Gastroenterol; 2003 Dec; 9(12):2666-70. PubMed ID: 14669309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.